The French National Agency for the Safety of Medicines and Health Products (ANSM) warns doctors about the risks of prescribing valproate to men of reproductive age - 09/08/24

L’Agence nationale de sécurité du médicament et des produits de santé (ANSM) met en garde les médecins contre les risques liés à la prescription de valproate chez les hommes en age de procréer

Guillaume Fond ^{a, d,} ⁎ , Dong Keon Yon ^{b, c}, Tham Thi Nguyen ^e, Bach Tran ^a, Lee Smith ^f, Laurent Boyer ^{a, d}

^a CEReSS, Research Centre on Health Services and Quality of Life, Aix Marseille University, 27, boulevard Jean-Moulin, Marseille, France 

^b Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, Republic of Korea 

^c Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea 

^d Fondation FondaMental, Créteil, France 

^e Institute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam 

^f Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, United Kingdom 

^*Corresponding author. CEReSS, Research Centre on Health Services and Quality of Life, Aix Marseille University, 27, boulevard Jean-Moulin, Marseille, France.CEReSS, Research Centre on Health Services and Quality of Life, Aix Marseille University27, boulevard Jean-MoulinMarseilleFrance

Le texte complet de cet article est disponible en PDF.